Info

The Psychedelic Podcast

The Psychedelic Podcast connects you to the leaders and pioneers of the psychedelic renaissance. From deep healing to creativity, leadership to spirituality, business, health, human performance, relationships, sexuality, and even culture itself—every aspect of our world is being transformed by psychedelic medicines. Get an inspired, informed, balanced look into how these powerful medicines are already being safely and responsibly used to catalyze both personal and collective transformation. Whether you’re just curious or a seasoned psychonaut, or somewhere in between, you’ll get insightful, practical, cutting-edge conversations from the forefront of the psychedelic movement. Join us as we explore how psychedelics can be integrated into culture for the evolution of humanity.
RSS Feed Subscribe in Apple Podcasts
The Psychedelic Podcast
2024
February
January


2023
December
November
October
September
August
July
June
May
April
March
February
January


2022
December
November
October
September
August
July
June
May
April
March
February
January


2021
December
October
September
August
June
May
April
March
February
January


2020
December
November
October
September
August
July
June
May
April
March
February
January


2019
December
November
October
January


2018
December
November
October
September
August
July
June
May
April
March
February
January


2017
August
July
June
May
April
March
February
January


All Episodes
Archives
Now displaying: December, 2022
Dec 26, 2022

Paul Austin is joined by Dr. Suresh Muthukumaraswamy, lead researcher in the world's first LSD microdosing clinical trial.

Find episode links, summary, and transcript here.

This is another special interview recorded on location at the 2022 Wonderland Conference in Miami, FL. Dr. Muthukumaraswamy shares the unique design of his LSD microdose trial, plans for future research, and how these studies might be received in New Zealand and around the globe.

Suresh completed his Ph.D. in psychology at the University of Auckland in 2005 after which he joined the newly established Cardiff University Brain Research Imaging Centre as a postdoctoral fellow. In 2014, Suresh received a Rutherford Discovery Fellowship and has returned to Auckland where he works in The School of Pharmacy (Faculty of Medicine and Health Sciences).

Suresh’s main research interests are in understanding how therapies alter brain activity and in developing methodologies to measure these changes in both healthy individuals and patient groups - particularly patients with depression. His previous studies have involved a range of compounds including hallucinogens (ketamine, LSD, psilocybin), anesthetics (propofol, dexmedetomidine), anti-epileptics (vigabatrin, perampanel, tiagabine) and GABA-enhancers (zolpidem, gaboxadol). Suresh’s research has used a wide-range of neuroimaging techniques including magnetoencephalography, electroencephalography, functional magnetic resonance imaging and magnetic resonance spectroscopy.

Highlights:

  • Dr. Muthukumaraswamy shares his academic and professional background, and what led him to studying psychedelics.
  • Dr. Muthukumaraswamy explains the origin story and unique design of his LSD microdosing study.
  • How study volunteers generally respond to microdosing in a lab vs. in their normal daily environments.
  • Design elements Dr. Muthukumaraswamy plans to implement in future LSD microdose studies.
  • Considering how Dr. Muthukumaraswamy’s take-home LSD microdose study might impact research and policy in other countries.
  • The legal landscape of psychedelics relevant to New Zealand’s indigenous Māori community.

Episode Links:

This podcast is brought to you by Third Wave's Mushroom Grow Kit. Get the tools you need to grow mushrooms along with an in-depth guide to finding spores.

This episode is brought to you by Apollo Neuro, the first scientifically validated wearable that actively improves your body’s resilience to stress. Apollo was developed by a friend of Third Wave, Dr. David Rabin M.D Ph.D., a neuroscientist and board-certified psychiatrist who has been studying the impact of chronic stress in humans for nearly 15 years. Third Wave listeners get 15% off—just use this link.

Dec 18, 2022

Matthew W. Johnson, Ph.D. joins Paul F. Austin to share his studies of psilocybin for smoking cessation, cancer distress treatment, and more

In this episode, we feature another special interview recorded at the 2022 Wonderland conference in Miami, FL.

Find episode links, summary, and transcript here.

Matthew W. Johnson, Ph.D. is the Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research at Johns Hopkins. Working with psychedelics since 2004, he is one of the world’s most widely published experts in the field. He has published research on psychedelics and mystical experience, personality change, tobacco smoking cessation, cancer distress treatment, and depression treatment. In 2021, as principal investigator, he received the first grant in 50 years from the US government for a treatment study with a classic psychedelic, specifically psilocybin in the treatment of tobacco addiction. He is also known for his expertise in behavioral economics, addiction, sexual risk behavior, and research with a wide variety of drug classes.

Highlights:

  • How Dr. Johnson’s own life has changed as a result of his years of research, including psilocybin for the treatment of cancer distress.
  • Dr. Johnson’s study on psilocybin for smoking cessation; the first US government-funded study on the therapeutic use of a psychedelic in 50 years.
  • The initial findings of psilocybin vs. nicotine patch as smoking-cessation treatments.
  • How Dr. Johnson plans to contribute to psychedelic research and oversight as the industry grows.
  • Dr. Johnson cautions psychedelic therapists against inappropriately pushing spiritual or religious frameworks onto patients.

Episode Links:

These show links may contain affiliate links. Third Wave receives a small percentage of the product price if you purchase through the above affiliate links.

This episode is brought to you by Apollo Neuro, the first scientifically validated wearable that actively improves your body’s resilience to stress. Apollo was developed by a friend of Third Wave, Dr. David Rabin M.D Ph.D., a neuroscientist and board-certified psychiatrist who has been studying the impact of chronic stress in humans for nearly 15 years. Third Wave listeners get 15% off—just use this link.

Dec 12, 2022

Rick Doblin, Ph.D., founder of MAPS, joins Paul F. Austin to discuss the healing of humanity through legalized psychedelic medicine.

This is another special interview from the 2022 Wonderland Conference in Miami, FL. Paul F. Austin is joined by MAPS founder Rick Doblin, Ph.D., to discuss the healing of humanity through legalized psychedelic medicine.

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana. His Master’s thesis was a survey of oncologists on smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and puppy, with three empty rooms from his children who have all graduated college and begun their life journeys. Learn more about Rick by listening to his Origin Story and watching his TED Talk.

Highlights:

  • Rick Doblin’s life (in five minutes), the origin story of MAPS, and the latest progress of its FDA clinical trials.
  • How MAPS has changed since Michael Pollan’s How To Change Your Mind Netflix documentary.
  • What keeps Rick focused, grounded and motivated to continue his work.
  • Why MAPS chose to work with MDMA for PTSD, and what its strategy will look like after FDA approval.
  • The novel financing strategies MAPS is taking in response to the ‘failure of philanthropy’.
  • Working towards mass mental health and a “global spiritualized humanity”.
  • MAPS’ Fourth Psychedelic Science Conference — June 2023.
  • How to “make a post-prohibition world work out” and empower people to deal with trauma, with and without substances.

Episode Links:

These show links may contain affiliate links. Third Wave receives a small percentage of the product price if you purchase through the above affiliate links.

This episode is brought to you by MycroDrops™ Powerful Micro-Elixirs made from Adaptogen and nootropic herbs and mushrooms. Get MOTIVATED, FOCUSED & GROUNDED! Use code THIRDWAVE and take $10 off your first purchase of $30 or more. Visit www.mycrodrops.com.

This episode is brought to you by Apollo Neuro, the first scientifically validated wearable that actively improves your body’s resilience to stress. Apollo was developed by a friend of Third Wave, Dr. David Rabin M.D Ph.D., a neuroscientist and board-certified psychiatrist who has been studying the impact of chronic stress in humans for nearly 15 years. Third Wave listeners get 15% off—just use this link.

Dec 5, 2022

This is an uncut interview recorded live at the 2022 Wonderland Conference in Miami, FL. Paul F. Austin is joined by renowned mycologist, author and researcher Paul Stamets, along with Pamela Kryskow, M.D., both co-founders of MycoMedica Life Sciences, PBC. They dive into all things microdosing, clinical trials, naturalistic science and patient-driven research, while exploring and honoring the wisdom of indigenous cultures around the world—and even martial arts.

Find episode links, summary, and transcript here.

Paul Stamets, speaker, author, mycologist, medical researcher and entrepreneur, is considered an intellectual and industry leader in fungi: habitat, medicinal use, and production. He lectures extensively to deepen the understanding and respect for the organisms that literally exist under every footstep taken on this path of life.

Paul’s philosophy is that “MycoDiversity is BioSecurity.” He sees the ancient Old Growth forests of the Pacific Northwest as a resource of incalculable value, especially in terms of its fungal genome. A dedicated hiker and explorer, his passion is to preserve and protect as many ancestral strains of mushrooms as possible from these pristine woodlands. His research is considered breakthrough by thought leaders for creating a paradigm shift for helping ecosystems worldwide.

Paul is the author of six books (including Mycelium Running: How Mushrooms Can Help Save the World, Growing Gourmet & Medicinal Mushrooms, and Psilocybin Mushrooms of the World). He has discovered and named several new species of psilocybin mushrooms.

Dr. Pamela Kryskow is a medical doctor with a strong interest in psychedelic medicine, mental health and chronic pain. She is a founding board member of the Canadian Psychedelic Association. She is also a part of an expert team working to give Canadians access to psilocybin at end of life.

Dr Kryskow is actively involved in research related to psilocybin, MDMA, ketamine, mental wellness and neurogenesis. She is a co-investigator on the largest microdosing study, Microdose.me, which is ongoing with 14 000+ enrolled participants.

A Clinical Instructor at University of British Columbia and Adjunct Professor at Vancouver Island University, Dr. Kryskow is also the medical lead on the Roots To Thrive Ketamine Assisted Therapy program, which treats healthcare providers with PTSD, depression, anxiety, and addiction. In real life, she loves foraging in the forest, ocean kayaking, growing kale and daydreaming in the hammock.

Highlights:

  • An introduction to Paul and Pam, and their work together in researching the benefits of microdosing psilocybin.
  • Tracking the history of mushroom wisdom and knowledge, from indigenous traditions to scientific research.
  • How the complexity of microdosing demands new research approaches and methodologies.
  • Addressing the disconnect between policy and science.
  • Paul Stamets’ vision of how psychedelics can be integrated in society, and how MycoMedica is working towards it.
  • How new scientific findings on psilocybin and microdosing could influence future legislation.
  • Closing remarks: psychedelics, kindness, and community

Episode Links

This episode is brought to you by MycroDrops™ Powerful Micro-Elixirs made from Adaptogen and nootropic herbs and mushrooms. Get MOTIVATED, FOCUSED & GROUNDED! Use code THIRDWAVE and take $10 off your first purchase of $30 or more. Visit www.mycrodrops.com.

This episode is brought to you by Apollo Neuro, the first scientifically validated wearable that actively improves your body’s resilience to stress. Apollo was developed by a friend of Third Wave, Dr. David Rabin M.D Ph.D., a neuroscientist and board-certified psychiatrist who has been studying the impact of chronic stress in humans for nearly 15 years. Third Wave listeners get 15% off—just use this link.

1